Market revenue in 2023 | USD 222.1 million |
Market revenue in 2030 | USD 379.0 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Endocrine signaling |
Fastest growing segment | Endocrine Signaling |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Endocrine Signaling, Paracrine Signaling, Autocrine Signaling |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Becton Dickinson & Co, Bio-Rad Laboratories Inc, Bio-Techne Corp, Cell Signaling Technology, Danaher Corp, Merck KGaA, PerkinElmer, Promega |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell signaling market will help companies and investors design strategic landscapes.
Endocrine signaling was the largest segment with a revenue share of 43.04% in 2023. Horizon Databook has segmented the Middle East & Africa cell signaling market based on endocrine signaling, paracrine signaling, autocrine signaling covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell signaling market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell signaling market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account